A detailed history of High Tower Advisors, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, High Tower Advisors, LLC holds 147,400 shares of RVNC stock, worth $378,818. This represents 0.0% of its overall portfolio holdings.

Number of Shares
147,400
Previous 535,387 72.47%
Holding current value
$378,818
Previous $1.38 Million 72.51%
% of portfolio
0.0%
Previous 0.0%

Shares

25 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$2.57 - $2.57 $997,126 - $997,126
-387,987 Reduced 72.47%
147,400 $378,000
Q2 2024

Aug 13, 2024

BUY
$2.34 - $4.73 $210,600 - $425,700
90,000 Added 20.21%
535,387 $1.38 Million
Q1 2024

May 06, 2024

BUY
$4.65 - $9.31 $181,191 - $362,773
38,966 Added 9.59%
445,387 $2.19 Million
Q4 2023

Feb 12, 2024

BUY
$5.81 - $11.2 $679,305 - $1.31 Million
116,920 Added 40.39%
406,421 $3.57 Million
Q3 2023

Nov 08, 2023

BUY
$11.47 - $25.07 $1.08 Million - $2.37 Million
94,451 Added 48.42%
289,501 $3.32 Million
Q2 2023

Aug 14, 2023

SELL
$24.7 - $37.61 $2.72 Million - $4.14 Million
-110,209 Reduced 36.1%
195,050 $4.94 Million
Q1 2023

May 11, 2023

SELL
$18.36 - $35.27 $3.42 Million - $6.57 Million
-186,183 Reduced 37.89%
305,259 $9.83 Million
Q4 2022

Feb 08, 2023

SELL
$18.32 - $30.66 $6.67 Million - $11.2 Million
-363,992 Reduced 42.55%
491,442 $9.07 Million
Q3 2022

Nov 09, 2022

SELL
$14.33 - $28.47 $5.28 Million - $10.5 Million
-368,728 Reduced 30.12%
855,434 $23.1 Million
Q2 2022

Aug 10, 2022

SELL
$11.52 - $20.4 $103,426 - $183,151
-8,978 Reduced 0.73%
1,224,162 $16.9 Million
Q1 2022

May 12, 2022

BUY
$12.36 - $20.31 $3.28 Million - $5.39 Million
265,422 Added 27.43%
1,233,140 $24 Million
Q4 2021

Feb 10, 2022

BUY
$12.46 - $27.87 $1.34 Million - $3 Million
107,814 Added 12.54%
967,718 $15.8 Million
Q3 2021

Nov 12, 2021

BUY
$25.78 - $33.21 $7.14 Million - $9.2 Million
277,129 Added 47.55%
859,904 $24 Million
Q2 2021

Aug 06, 2021

SELL
$26.8 - $31.84 $2.79 Million - $3.32 Million
-104,240 Reduced 15.17%
582,775 $17.3 Million
Q1 2021

May 10, 2021

BUY
$24.03 - $29.97 $14.8 Million - $18.4 Million
614,315 Added 845.0%
687,015 $19.2 Million
Q4 2020

Feb 10, 2021

SELL
$23.41 - $28.34 $567,317 - $686,791
-24,234 Reduced 25.0%
72,700 $2.06 Million
Q3 2020

Nov 13, 2020

BUY
$23.23 - $34.3 $1.11 Million - $1.64 Million
47,734 Added 97.02%
96,934 $2.44 Million
Q2 2020

Aug 10, 2020

BUY
$12.6 - $26.55 $69,300 - $146,025
5,500 Added 12.59%
49,200 $1.2 Million
Q1 2020

May 21, 2020

BUY
$12.46 - $27.81 $33,642 - $75,087
2,700 Added 6.59%
43,700 $648,000
Q4 2019

Feb 14, 2020

BUY
$11.66 - $20.15 $149,248 - $257,919
12,800 Added 45.39%
41,000 $665,000
Q3 2019

Nov 12, 2019

BUY
$10.22 - $14.5 $10,220 - $14,500
1,000 Added 3.68%
28,200 $367,000
Q2 2019

Aug 13, 2019

BUY
$10.67 - $15.49 $12,804 - $18,588
1,200 Added 4.62%
27,200 $352,000
Q1 2019

May 15, 2019

BUY
$15.4 - $20.39 $92,400 - $122,340
6,000 Added 30.0%
26,000 $410,000
Q4 2018

Feb 14, 2019

SELL
$18.06 - $24.96 $36,120 - $49,920
-2,000 Reduced 9.09%
20,000 $403,000
Q4 2017

Feb 14, 2018

BUY
$24.55 - $36.3 $540,100 - $798,599
22,000
22,000 $787,000

Others Institutions Holding RVNC

About Revance Therapeutics, Inc.


  • Ticker RVNC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 82,305,696
  • Market Cap $212M
  • Description
  • Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...
More about RVNC
Track This Portfolio

Track High Tower Advisors, LLC Portfolio

Follow High Tower Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of High Tower Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on High Tower Advisors, LLC with notifications on news.